Author

C. E. Mills

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2 Bioengineering· 1 Biophysics· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:statistical model· 4 Research Focus:drug response / drug discovery· 3 Approach:experimental assay· 3 Organism:human· 3 Assay:proteomics· 3 Organism:bacteria (other)· 2 Approach:deep learning· 2 Assay:bulk RNA-seq· 1

Frequent Co-Authors

D. Tullman-Ercek· 2 shared M. Chung· 2 shared M. Olvera de la Cruz· 2 shared N. W. Kennedy· 2 shared S. A. Boswell· 2 shared A. D. Axtman· 1 shared A. D. Jackson· 1 shared A. G. Archer· 1 shared

Activity by Year

2019-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 17 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersBioengineering

D. Tullman-Ercek

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Vertex protein PduN tunes encapsulated pathway performance by dictating bacterial metabolosome morphology

C. E. Mills, C. Waltmann, A. G. Archer, N. W. Kennedy, C. H. Abrahamson, A. D. Jackson, E. W. Roth, S. Shirman, M. C. Jewett, N. M. Mangan, M. Olvera de la Cruz, D. Tullman-Ercek

The paper investigates how removing the vertex protein PduN alters the morphology of the Pdu MCP microcompartment in Salmonella, affecting pathway performance through changes in surface area to volume ratios.

bioRxiv · Oct 31, 2021Bioengineering

Integrating multi-omics data reveals function and therapeutic potential of deubiquitinating enzymes

L. M. Doherty, C. E. Mills, S. A. Boswell, X. Liu, C. T. Hoyt, B. M. Gyori, S. J. Buhrlage, P. K. Sorger

This study integrates multi-omics data to identify DUB functions and therapeutic targets, revealing key enzymes like USP14, UCHL5, and USP7 with potential in cancer therapy.

bioRxiv · Aug 6, 2021Cancer Biology

Computational and experimental approaches to controlling bacterial microcompartment assembly

Y. Li, N. W. Kennedy, S. Li, C. E. Mills, D. Tullman-Ercek, M. Olvera de la Cruz

The paper uses computational and experimental methods to control bacterial microcompartment assembly by modifying protein interactions and angles.

bioRxiv · Jan 18, 2021Biophysics

The Kinase Chemogenomic Set (KCGS): An open science resource for kinase vulnerability identification

C. I. Wells, H. Al-Ali, D. M. Andrews, C. R. M. Asquith, A. D. Axtman, M. Chung, I. Dikic, D. Ebner, J. Elkins, P. Ettmayer, C. Fischer, M. Frederiksen, N. S. Gray, S. B. Hatch, S. Knapp, , D. H. Drewry

The paper introduces the Kinase Chemogenomic Set (KCGS), a curated collection of 187 selective kinase inhibitors covering 215 human kinases, for use in cell-based screens.

bioRxiv · Dec 22, 2019Cell Biology

Multi-omics profiling establishes the polypharmacology of FDA Approved CDK4/6 inhibitors and the potential for differential clinical activity

M. Hafner, C. E. Mills, K. Subramanian, C. Chen, M. Chung, S. A. Boswell, R. A. Everley, C. Liu, C. S. Walmsley, D. Juric, P. Sorger

This study compares the mechanisms of three FDA-approved CDK4/6 inhibitors and finds significant differences in their transcriptional, proteomic, and cellular effects, suggesting potential for differential clinical use.

bioRxiv · Mar 19, 2019Cancer Biology